tiprankstipranks
Trending News
More News >
Hologic (HOLX)
NASDAQ:HOLX
US Market
Advertisement

Hologic (HOLX) Stock Forecast & Price Target

Compare
1,002 Followers
See the Price Targets and Ratings of:

HOLX Analyst Ratings

Moderate Buy
13Ratings
Moderate Buy
4 Buy
9 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Hologic
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HOLX Stock 12 Month Forecast

Average Price Target

$77.70
▲(5.03% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Hologic in the last 3 months. The average price target is $77.70 with a high forecast of $94.00 and a low forecast of $69.00. The average price target represents a 5.03% change from the last price of $73.98.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"56":"$56","95":"$95","65.75":"$65.8","75.5":"$75.5","85.25":"$85.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$94.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$77.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$69.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[56,65.75,75.5,85.25,95],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.04,69.11384615384615,71.18769230769232,73.26153846153846,75.33538461538461,77.40923076923077,79.48307692307692,81.55692307692308,83.63076923076923,85.70461538461538,87.77846153846154,89.85230769230769,91.92615384615385,{"y":94,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.04,67.86,68.68,69.5,70.32000000000001,71.14,71.96000000000001,72.78,73.60000000000001,74.42,75.24000000000001,76.06,76.88,{"y":77.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.04,67.19076923076923,67.34153846153846,67.49230769230769,67.64307692307693,67.79384615384616,67.94461538461539,68.09538461538462,68.24615384615385,68.39692307692307,68.54769230769232,68.69846153846154,68.84923076923077,{"y":69,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":80.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.09,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.14,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.39,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.28,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.33,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$94.00Average Price Target$77.70Lowest Price Target$69.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Raymond James Analyst forecast on HOLX
Raymond James
Raymond James
$79
Hold
6.79%
Upside
Downgraded
10/22/25
Hologic downgraded to Market Perform from Outperform at Raymond JamesHologic downgraded to Market Perform from Outperform at Raymond James
Stephens
$78$76
Hold
2.73%
Upside
Downgraded
10/22/25
Hologic downgraded to Equal Weight from Overweight at StephensHologic downgraded to Equal Weight from Overweight at Stephens
William Blair Analyst forecast on HOLX
William Blair
William Blair
Hold
Downgraded
10/21/25
William Blair downgrades Hologic (HOLX) to a HoldWe are yet to see details on these goals but believe the breast health business is on its path back to normalized revenue growth and the launch of Envision (the next-generation gantry) should accelerate this growth.
J.P. Morgan Analyst forecast on HOLX
J.P. Morgan
J.P. Morgan
$80$78
Hold
5.43%
Upside
Downgraded
10/21/25
Hologic downgraded to Neutral from Overweight at JPMorganHologic downgraded to Neutral from Overweight at JPMorgan
Needham
Hold
Reiterated
10/21/25
Hologic's Acquisition by TPG and Blackstone: Hold Rating Amid Lower Valuation and Antitrust ConcernsWe note that there were previous reports that TPG and Blackstone had offered $16B to take HOLX private but that HOLX turned down this offer. The non-tradable deal CVR of up to $3.00 per share is expected in two payments of $1.50 based upon achievement of certain global revenue goals for HOLX’s Breast Health business in FY26 and FY27 (milestone terms not disclosed). Assuming the CVR is awarded, TPG and Blackstone are paying 17.6x our CY26E EPS estimate (or 16.9x our CY26E EPS if the CVR is not awarded), which is below our large-cap med tech peers, which trades at a median 2026E P/E multiple of 21.7x. However, we believe the discount is warranted since HOLX is growing more slowly than its peers. The transaction is expected to close in F1H26 and includes a 45-day "go-shop" period where HOLX can solicit competing bids.
Leerink Partners Analyst forecast on HOLX
Leerink Partners
Leerink Partners
$70$78
Hold
5.43%
Upside
Reiterated
10/21/25
Hold Rating on Hologic Amid Acquisition by Blackstone and TPG: Limited Impact on Diagnostics SectorWe see limited readthrough to the rest of our Dx coverage, due to the uniqueness of Panther and cytology compared to more CLIA-oriented testing at other labs. The traction is expected to close in calendar 1H26. The deal has been speculated on for a long time and unlikely to be viewed as a surprise by investors. Though this deal is relatively unique and was speculated upon for a while, we do believe M&A sentiment could lift slightly as portfolios are trimmed (WAT-BDX deal [WAT rated OP, BDX not rated]) and as assets are acquired by private equity (HOLX deal).
TR | OpenAI - 4o Analyst forecast on HOLX
TR | OpenAI - 4o
TR | OpenAI - 4o
$70$73
Hold
-1.32%
Downside
Reiterated
10/16/25
AI Generated ArticleAI Generated Article
Evercore ISI Analyst forecast on HOLX
Evercore ISI
Evercore ISI
$69$78
Buy
5.43%
Upside
Upgraded
10/07/25
Hologic upgraded to Outperform from In Line at Evercore ISIHologic upgraded to Outperform from In Line at Evercore ISI
BTIG
Hold
Reiterated
09/25/25
Hologic's Growth Potential: Hold Rating Amidst Uncertainties and Transient Headwinds
RBC Capital Analyst forecast on HOLX
RBC Capital
RBC Capital
$87$94
Buy
27.06%
Upside
Reiterated
09/02/25
Hologic (HOLX) Gets a Buy from RBC Capital
Argus Research Analyst forecast on HOLX
Argus Research
Argus Research
$80
Buy
8.14%
Upside
Upgraded
08/18/25
Hologic upgraded to Buy from Hold at ArgusHologic upgraded to Buy from Hold at Argus
Mizuho Securities Analyst forecast on HOLX
Mizuho Securities
Mizuho Securities
$70$75
Buy
1.38%
Upside
Reiterated
07/31/25
Hologic price target raised to $75 from $70 at MizuhoHologic price target raised to $75 from $70 at Mizuho
Morgan Stanley Analyst forecast on HOLX
Morgan Stanley
Morgan Stanley
$65$69
Hold
-6.73%
Downside
Reiterated
07/31/25
Morgan Stanley Sticks to Its Hold Rating for Hologic (HOLX)Hologic, Inc.’s Equal‐Weight rating is supported by a PT adjustment from 65 to 69.
UBS
$65$70
Hold
-5.38%
Downside
Reiterated
07/31/25
UBS Reaffirms Their Hold Rating on Hologic (HOLX)UBS analyst Elizabeth Garcia raised the price target on Hologic (NASDAQ: HOLX) to $70.00 (from $65.00) while maintaining a Neutral rating.
Bank of America Securities Analyst forecast on HOLX
Bank of America Securities
Bank of America Securities
$64$70
Hold
-5.38%
Downside
Reiterated
07/18/25
Bank of America Securities Sticks to Their Hold Rating for Hologic (HOLX)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Raymond James Analyst forecast on HOLX
Raymond James
Raymond James
$79
Hold
6.79%
Upside
Downgraded
10/22/25
Hologic downgraded to Market Perform from Outperform at Raymond JamesHologic downgraded to Market Perform from Outperform at Raymond James
Stephens
$78$76
Hold
2.73%
Upside
Downgraded
10/22/25
Hologic downgraded to Equal Weight from Overweight at StephensHologic downgraded to Equal Weight from Overweight at Stephens
William Blair Analyst forecast on HOLX
William Blair
William Blair
Hold
Downgraded
10/21/25
William Blair downgrades Hologic (HOLX) to a HoldWe are yet to see details on these goals but believe the breast health business is on its path back to normalized revenue growth and the launch of Envision (the next-generation gantry) should accelerate this growth.
J.P. Morgan Analyst forecast on HOLX
J.P. Morgan
J.P. Morgan
$80$78
Hold
5.43%
Upside
Downgraded
10/21/25
Hologic downgraded to Neutral from Overweight at JPMorganHologic downgraded to Neutral from Overweight at JPMorgan
Needham
Hold
Reiterated
10/21/25
Hologic's Acquisition by TPG and Blackstone: Hold Rating Amid Lower Valuation and Antitrust ConcernsWe note that there were previous reports that TPG and Blackstone had offered $16B to take HOLX private but that HOLX turned down this offer. The non-tradable deal CVR of up to $3.00 per share is expected in two payments of $1.50 based upon achievement of certain global revenue goals for HOLX’s Breast Health business in FY26 and FY27 (milestone terms not disclosed). Assuming the CVR is awarded, TPG and Blackstone are paying 17.6x our CY26E EPS estimate (or 16.9x our CY26E EPS if the CVR is not awarded), which is below our large-cap med tech peers, which trades at a median 2026E P/E multiple of 21.7x. However, we believe the discount is warranted since HOLX is growing more slowly than its peers. The transaction is expected to close in F1H26 and includes a 45-day "go-shop" period where HOLX can solicit competing bids.
Leerink Partners Analyst forecast on HOLX
Leerink Partners
Leerink Partners
$70$78
Hold
5.43%
Upside
Reiterated
10/21/25
Hold Rating on Hologic Amid Acquisition by Blackstone and TPG: Limited Impact on Diagnostics SectorWe see limited readthrough to the rest of our Dx coverage, due to the uniqueness of Panther and cytology compared to more CLIA-oriented testing at other labs. The traction is expected to close in calendar 1H26. The deal has been speculated on for a long time and unlikely to be viewed as a surprise by investors. Though this deal is relatively unique and was speculated upon for a while, we do believe M&A sentiment could lift slightly as portfolios are trimmed (WAT-BDX deal [WAT rated OP, BDX not rated]) and as assets are acquired by private equity (HOLX deal).
TR | OpenAI - 4o Analyst forecast on HOLX
TR | OpenAI - 4o
TR | OpenAI - 4o
$70$73
Hold
-1.32%
Downside
Reiterated
10/16/25
AI Generated ArticleAI Generated Article
Evercore ISI Analyst forecast on HOLX
Evercore ISI
Evercore ISI
$69$78
Buy
5.43%
Upside
Upgraded
10/07/25
Hologic upgraded to Outperform from In Line at Evercore ISIHologic upgraded to Outperform from In Line at Evercore ISI
BTIG
Hold
Reiterated
09/25/25
Hologic's Growth Potential: Hold Rating Amidst Uncertainties and Transient Headwinds
RBC Capital Analyst forecast on HOLX
RBC Capital
RBC Capital
$87$94
Buy
27.06%
Upside
Reiterated
09/02/25
Hologic (HOLX) Gets a Buy from RBC Capital
Argus Research Analyst forecast on HOLX
Argus Research
Argus Research
$80
Buy
8.14%
Upside
Upgraded
08/18/25
Hologic upgraded to Buy from Hold at ArgusHologic upgraded to Buy from Hold at Argus
Mizuho Securities Analyst forecast on HOLX
Mizuho Securities
Mizuho Securities
$70$75
Buy
1.38%
Upside
Reiterated
07/31/25
Hologic price target raised to $75 from $70 at MizuhoHologic price target raised to $75 from $70 at Mizuho
Morgan Stanley Analyst forecast on HOLX
Morgan Stanley
Morgan Stanley
$65$69
Hold
-6.73%
Downside
Reiterated
07/31/25
Morgan Stanley Sticks to Its Hold Rating for Hologic (HOLX)Hologic, Inc.’s Equal‐Weight rating is supported by a PT adjustment from 65 to 69.
UBS
$65$70
Hold
-5.38%
Downside
Reiterated
07/31/25
UBS Reaffirms Their Hold Rating on Hologic (HOLX)UBS analyst Elizabeth Garcia raised the price target on Hologic (NASDAQ: HOLX) to $70.00 (from $65.00) while maintaining a Neutral rating.
Bank of America Securities Analyst forecast on HOLX
Bank of America Securities
Bank of America Securities
$64$70
Hold
-5.38%
Downside
Reiterated
07/18/25
Bank of America Securities Sticks to Their Hold Rating for Hologic (HOLX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hologic

1 Month
xxx
Success Rate
7/9 ratings generated profit
78%
Average Return
+3.11%
upgraded a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 77.78% of your transactions generating a profit, with an average return of +3.11% per trade.
3 Months
xxx
Success Rate
6/9 ratings generated profit
67%
Average Return
+1.83%
upgraded a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +1.83% per trade.
1 Year
Vijay KumarEvercore ISI
Success Rate
7/9 ratings generated profit
78%
Average Return
+18.54%
upgraded a buy rating 16 days ago
Copying Vijay Kumar's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +18.54% per trade.
2 Years
xxx
Success Rate
9/9 ratings generated profit
100%
Average Return
+24.52%
upgraded a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +24.52% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HOLX Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
0
0
0
0
0
Buy
7
12
11
12
7
Hold
15
22
14
16
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
34
25
28
15
In the current month, HOLX has received 7 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. HOLX average Analyst price target in the past 3 months is 77.70.
Each month's total comprises the sum of three months' worth of ratings.

HOLX Financial Forecast

HOLX Earnings Forecast

Next quarter’s earnings estimate for HOLX is $1.10 with a range of $1.05 to $1.11. The previous quarter’s EPS was $1.08. HOLX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year HOLX has Preformed in-line its overall industry.
Next quarter’s earnings estimate for HOLX is $1.10 with a range of $1.05 to $1.11. The previous quarter’s EPS was $1.08. HOLX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year HOLX has Preformed in-line its overall industry.

HOLX Sales Forecast

Next quarter’s sales forecast for HOLX is $1.03B with a range of $1.03B to $1.04B. The previous quarter’s sales results were $1.02B. HOLX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year HOLX has Preformed in-line its overall industry.
Next quarter’s sales forecast for HOLX is $1.03B with a range of $1.03B to $1.04B. The previous quarter’s sales results were $1.02B. HOLX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year HOLX has Preformed in-line its overall industry.

HOLX Stock Forecast FAQ

What is HOLX’s average 12-month price target, according to analysts?
Based on analyst ratings, Hologic’s 12-month average price target is 77.70.
    What is HOLX’s upside potential, based on the analysts’ average price target?
    Hologic has 5.03% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is HOLX a Buy, Sell or Hold?
          Hologic has a consensus rating of Moderate Buy which is based on 4 buy ratings, 9 hold ratings and 0 sell ratings.
            What is Hologic’s price target?
            The average price target for Hologic is 77.70. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $94.00 ,the lowest forecast is $69.00. The average price target represents 5.03% Increase from the current price of $73.98.
              What do analysts say about Hologic?
              Hologic’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of HOLX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis